



**meetings
in a box**

ROAD TO 
ASCO 2026

A cura di Annalice Gandini, Parigi (FR)

GASTROINTESTINAL CANCER – Colorectal cancer

LOCALIZED DISEASE

- **CIRCULATE (Folprecht – LBA3500)**
DFS and TTR with ctDNA-based decision for adjuvant treatment in colon cancer stage II (CIRCULATE): An AIO (KRK- 0217)/ABCSG trial.
- **CIRCULATE-Japan GALAXY (Yamamoto – Abstract 3501)**
Informing optimal duration of adjuvant chemotherapy in resected stage I-IV CRC based on early ctDNA dynamics.
- **EPISODE-III (Takashima – LBA3508)**
Adjuvant aspirin for stage III CRC after curative resection: Primary analysis of the randomized double-blind placebo-controlled phase 3 trial (EPISODE-III: JCOG1503C).

GASTROINTESTINAL CANCER – Colorectal cancer

ADVANCED DISEASE

- **BREAKWATER (Kopetz – LBA3503)**
PFS and OS analyses of 1L encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant mCRC

GASTROINTESTINAL CANCER – Other GI cancers

- **Pancreatic cancer | RASolute 302 (Wolpin – LBA5)**
Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study.
- **HCC | EMERALD-3 (Abou-Alfa – LBA4000)**
Efficacy and safety results from EMERALD-3: A phase 3, randomized study of tremelimumab plus durvalumab +/- lenvatinib combined with TACE in pts with unresectable embolization-eligible HCC.
- **Gastric cancer | Serplulimab in localized GC (Shen – Abstract 4009)** Neoadjuvant/adjuvant serplulimab (anti-PD1) vs placebo combined with chemotherapy for PD-L1–positive gastric cancer: A randomized, double-blind, multicenter phase 3 study.
- **Cholangiocarcinoma | FIGHT-302 (Bekaii-Saab – Abstract 4017)**
Pemigatinib for untreated unresectable/metastatic cholangiocarcinoma with FGFR2 rearrangement: Phase 3 FIGHT-302 results.

BREAST CANCER

LOCALIZED DISEASE

- **OPTIMA (Stein – Abstract 500)**

First results from the OPTIMA phase 3 randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk **ER-positive HER2-negative** early breast cancer.

- **KEYNOTE-522 (Schmid – Abstract 507)**

Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage **TNBC**: Final analysis results from the phase 3 KEYNOTE-522 study. (Updated analysis after median follow-up of 93.8 months).

BREAST CANCER

ADVANCED DISEASE

- **ASCENT-04 (Tolaney – Abstract 1013)**
ASCENT-04: Analysis of efficacy by biomarker subgroups (tBRCA, Trop2, HER2) with sacituzumab govitecan (SG) + pembrolizumab (pembro) vs CT + pembro in pts with previously untreated PD-L1+ mTNBC.
- **ASCENT-04 (Kalinsky – LBA1000)**
PFS₂ and subsequent therapies in the ASCENT-04 study of pts with previously untreated PD-L1+ mTNBC treated with sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs CT plus pembro.
- **ASCENT-03 (Barrios – Abstract 1014)**
ASCENT-03: Efficacy by biomarker subgroup (tBRCA, Trop2, HER2) with sacituzumab govitecan (SG) vs CT in pts with previously untreated mTNBC who are not candidates for PD-(L)1 inhibitors (PD-[L]1i).
- **ASCENT-03 (Hurvitz – Abstract 1001)**
PFS₂ and subsequent therapies in the ASCENT-03 study of pts with previously untreated mTNBC treated with sacituzumab govitecan (SG) vs CT.
- **SERENA-6 (Bidard – LBA1007)**
First-line (1L) camizestrant (CAMI) for emergent ESR1 mutations (ESR1m) in advanced breast cancer (ABC): Final progression-free survival 2 (PFS₂) from the phase III SERENA-6 trial.

LUNG CANCER

LOCALIZED DISEASE

- **LIBRETTO-432 (Goldman – LBA3)**

EFS with adjuvant selpercatinib in stage IB-III A **RET fusion-positive** NSCLC: Primary results of the phase 3 LIBRETTO-432 trial.

LUNG CANCER

ADVANCED DISEASE - NSCLC

- **WU-KONG28 (Heymach – LBA8500)**
Sunvozertinib monotherapy versus platinum-based chemotherapy as 1L for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational phase 3 randomized study (WU-KONG28).
- **NCT05256290 phase 2 (Rotow – Abstract 8519)**
Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in treatment-naïve patients with NSCLC with non-classical EGFR mutations.
- **AcceleRET-Lung (Popat – Abstract 8504)**
Efficacy and safety of pralsetinib as first-line treatment of RET fusion-positive advanced or metastatic NSCLC: The phase 3 AcceleRET-Lung study.

LUNG CANCER

OTHER LUNG CANCERS

- **HARMONi-6 (Zhiwei – LBA₄)**

Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced **squamous** NSCLC: Overall survival results of the phase 3 HARMONi-6 trial.

- **Autologous NK cell infusion in limited SCLC (Cui – Abstract 8013)**

Autologous natural killer cell infusion as consolidation therapy after first-line chemoradiotherapy for limited-stage **SCLC**: A randomized, controlled, open-label, single-center phase 2 clinical study.

GENITOURINARY CANCERS

PROSTATE CANCER

- **NRG/RTOG 9202, 9413, 9902, and 0521 (Krishnan – Abstract 5000)**
Clinico-transcriptomic risk stratification to guide abiraterone treatment intensification in high-risk prostate cancer: A combined analysis of NRG/RTOG 9202, 9413, 9902, and 0521.
- **Transcriptomic profile in ENZAMET study (Sweeney – Abstract 5001)**
Assessment of the ability of Decipher Prostate Genomic Classifier (DGC) >0.85 to identify patients who benefit from adding docetaxel (DOC) to ADT plus enzalutamide (ENZ): Level 1B evidence from the ENZAMET study.
- **ECOG-ACRIN E3805 (Mamunur – Abstract 5002)**
Spatial transcriptomics-guided computational pathology model to stratify docetaxel benefit in metastatic hormone-sensitive prostate cancer: CHARTED trial (ECOG-ACRIN E3805).
- **TALAPRO-3 (Agarwal – LBA5007)**
Talazoparib + enzalutamide compared with placebo + ENZA for the treatment of pts with mCSPC harboring homologous recombination repair (HRR) gene alterations.
- **PROTEUS (Taplin – LBA1)**
Perioperative apalutamide (APA) + ADT vs placebo + ADT with radical prostatectomy (RP) in high-risk localized or locally advanced prostate cancer (HR LPC/LAPC): Final analysis of the PROTEUS phase 3 study.

GENITOURINARY CANCERS

UROTHELIAL CANCER

- **MAIN-CAV (Gupta – Abstract 4514)**

Phase 3 randomized trial of maintenance cabozantinib and avelumab versus avelumab after 1L platinum-based CT in pts with locally advanced/metastatic urothelial cancer (Alliance A032901).

GENITOURINARY CANCERS

RENAL CELL CARCINOMA

- **ctDNA in KEYNOTE-564 (Choueiri – Abstract 4502)**
ctDNA analysis in participants with renal cell carcinoma treated with adjuvant pembrolizumab or placebo in the KEYNOTE-564 trial.
- **CaboNivo in nccRCC (Feldman - Abstract 4521)**
Final results of a phase 2 trial of cabozantinib plus nivolumab (CaboNivo) in patients with non-clear cell renal cell carcinoma (nccRCC).

GYNECOLOGIC CANCERS

OVARIAN CANCER

- **ROSELLA (Gilbert – Abstract 5503)**

OS subgroup analyses for prior taxane use in the phase 3 ROSELLA trial of relacorilant (selective glucocorticoid receptor modulator, SGRM) plus nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023).

- **MIROVA (Harter – Abstract 5506)**

A randomized phase 2 trial of mirvetuximab soravtansine in folate receptor alpha (FR α)-high recurrent ovarian cancer eligible for platinum-based chemotherapy (MIROVA/AGO-OVAR 2.34).

GYNECOLOGIC CANCERS

ENDOMETRIAL CANCER

- **Update RUBY trial (Powell – Abstract 5501)**
Long-term survival rates and cure modeling with dostarlimab plus chemotherapy in dMMR/MSI-H primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.
- **Update NRG-GY018 (Nassef Eskander – Abstract 5502)**
Updated OS analysis and examination of subsequent therapy in endometrial cancer patients treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo in the NRG- GY018 trial.

OTHER CANCERS

- **GIST (Wagner – Abstract 11500)**

Primary results of the phase 3 Peak study of bezuclastinib + sunitinib vs sunitinib monotherapy in advanced gastrointestinal stromal tumors (GIST).

- **Sarcoma (Dickson – LBA2)**

SARCo41: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.

- **Glioma (Cloughesy – Abstract 2010)**

A global, randomized, double-blinded, phase 3 trial of vorasidenib vs placebo in patients with grade 2 glioma with an IDH1/2 mutation (INDIGO): Updated efficacy and safety.

- **Nasopharyngeal carcinoma (Liang – Abstract 6003)**

Two-cycle versus three-cycle induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3 randomized non inferiority trial.

OTHER CANCERS

- **Melanoma (Carlino – Abstract 9500)**

Individualized neoantigen therapy intismeran autogene (individualized, mRNA-based cancer vaccine) plus pembrolizumab (pembro) in resected melanoma: 5-year update of the KEYNOTE-942 study.

- **Merkel cell carcinoma (Bhatia - LBA9504)**

ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in patients with Merkel cell carcinoma and lymph node metastases.

- **Multicancer (Giridhar – LBA10509)**

Safety and performance results from PATHFINDER 2, a registrational study of a multi-cancer early detection (MCED) test in an intended-use population.